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OBJECTIVE — To determine the proportion of the American population who would merit
metformintreatment,accordingtorecentAmericanDiabetesAssociation(ADA)consensuspanel
recommendations to prevent or delay the development of diabetes.
RESEARCH DESIGN AND METHODS — Risk factors were evaluated in 1,581 Screen-
ing for Impaired Glucose Tolerance (SIGT), 2,014 Third National Health and Nutrition Exam-
ination Survey (NHANES III), and 1,111 National Health and Nutrition Examination Survey
2005–2006 (NHANES 2005–2006) subjects, who were non-Hispanic white and black, without
knowndiabetes.Criteriaforconsiderationofmetforminincludedthepresenceofbothimpaired
fasting glucose (IFG) and impaired glucose tolerance (IGT), with 1 additional diabetes risk
factor:age60years,BMI35kg/m
2,familyhistoryofdiabetes,elevatedtriglycerides,reduced
HDL cholesterol, hypertension, or A1C 6.0%.
RESULTS — Isolated IFG, isolated IGT, and IFG and IGT were found in 18.0, 7.2, and 8.2%
of SIGT; 22.3, 6.4, and 9.4% of NHANES III; and 21.8, 5.0, and 9.0% of NHANES 2005–2006
subjects, respectively. In SIGT, NHANES III, and NHANES 2005–2006, criteria for metformin
consideration were met in 99, 96, and 96% of those with IFG and IGT; 31, 29, and 28% of all
those with IFG; and 53, 57, and 62% of all those with IGT (8.1, 9.1, and 8.7% of all subjects),
respectively.
CONCLUSIONS — More than 96% of individuals with both IFG and IGT are likely to meet
ADAconsensuscriteriaforconsiderationofmetformin.Because28%ofallthosewithIFGmet
the criteria, providers should perform oral glucose tolerance tests to ﬁnd concomitant IGT in all
patients with IFG. To the extent that our ﬁndings are representative of the U.S. population, 1
in 12 adults has a combination of pre-diabetes and risk factors that may justify consideration of
metformin treatment for diabetes prevention.
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D
iabetes is a public health epidemic
(1) associated with high morbidity,
mortality (1), and cost (2). Cur-
rently,anestimated38millionAmericans
have the disease, nearly 40% of which is
undiagnosed, and another 87 million
have pre-diabetes: impaired fasting glu-
cose (IFG) and/or impaired glucose toler-
ance (IGT) (3). Diabetes develops
insidiously over several years, during
which time glucose metabolism
progresses slowly from normal to pre-
diabetesandthenmorerapidlytodiabetes.
Based on observational and prospective
studies, 25–40% of individuals with pre-
diabetesgoontodevelopdiabetesover3–8
years (4–6), and there is evidence of com-
plications in 50% of patients at the time of
diagnosis of diabetes (7).
Because progression from pre-
diabetes can be prevented or delayed by
lifestylechangeand/ormedication(4–6),
theAmericanDiabetesAssociation(ADA)
has issued a consensus statement recom-
mending early identiﬁcation and preven-
tive treatment in high-risk individuals
(8). The panel statement recommends
that individuals with both IFG and IGT
and one additional risk factor (age 60
years, BMI 35 kg/m
2, family history of
diabetes in ﬁrst-degree relative, elevated
triglycerides, reduced HDL cholesterol,
or A1C 6.0%) should be considered for
treatment with metformin, in addition to
lifestyle modiﬁcation, which includes
weight loss and physical activity.
To determine what proportion of the
American population presenting with ei-
ther IFG or IGT would merit consider-
ation for metformin treatment in
accordance with the recent ADA recom-
mendations, we evaluated healthy volun-
teers without known diabetes who were
screened for diabetes/pre-diabetes by the
75-g oral glucose tolerance test (OGTT).
RESEARCH DESIGN AND
METHODS— In cross-sectional
analyses, we evaluated the likelihood
that Americans with previously unrec-
ognized pre-diabetes would meet ADA
consensus panel recommendations for
consideration of metformin in addition
to change in lifestyle. Criteria for con-
sideration of metformin included the
presence of both IFG and IGT, with 1
additional diabetes risk factor: age 60
years,BMI 35kg/m
2,familyhistoryof
diabetes, elevated triglycerides, re-
duced HDL cholesterol, hypertension,
or A1C 6.0%.
Between 1 December 2005 and 31
March 2008, subjects were recruited to
participate in the Screening for Impaired
Glucose Tolerance (SIGT) study (9), a
cross-sectional study that was approved
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Theinvitationtoparticipatewasextended
toemployeesoftheGradyHealthSystem,
EmoryHealthCare,andEmoryUniversity
and Morehouse Schools of Medicine as
well as to members of the community.
Criteriaforeligibilitywereage18years,
non-Hispanic white or black race, no
prior diagnosis of diabetes, not pregnant
or breast-feeding, not taking glucocorti-
coids, and being well enough to have
worked during the previous week (with-
out requiring actual employment). Dur-
ing recruitment, 4,024 individuals
expressed initial interest in the study,
among whom 2,111 were scheduled for
ﬁrst visits (selected largely on the basis of
need to balance participant sex and race),
1,658 completed ﬁrst visits, and 1,581
completed the protocol. All study visits
were performed in the General Clinical
Research Centers at Emory University
Hospital and Grady Memorial Hospital.
All subjects gave written informed con-
sent before study participation.
We also evaluated subjects who took
partintheThirdNationalHealthandNu-
tritionExaminationSurvey(NHANESIII)
(10) and the continuous National Health
andNutritionExaminationSurvey2005–
2006 (NHANES 2005–2006) (11).
NHANES is a program of studies con-
ducted by the National Center for Health
Statistics of the Centers for Disease Con-
trol and Prevention that include both in-
terviews and physical examinations in a
nationally representative sample to assess
the health and nutritional status of adults
and children in the U.S. NHANES III was
conducted between 1988 and 1994. In
1999, the survey became a continuous
program examining 5,000 individuals
each year, which includes NHANES
2005–2006.
Measurements in the SIGT study
population
Demographic information was collected
by self-report and included family history
of diabetes in a ﬁrst-degree relative, race,
history of hypertension, history of diabe-
tes, and current medication use. Height
was measured with a stadiometer after
shoes were removed. Weight was mea-
sured using digital scales with subjects in
light clothing. Blood pressure was mea-
sured with digital manometers after sub-
jects had been seated quietly for 5 min.
Classiﬁcation of glucose tolerance
wasdeterminedbya75-gOGTTinaccor-
dance with ADA diagnostic criteria (12):
normal glucose tolerance (NGT)—fasting
plasma glucose (FPG) 100 mg/dl and
2-h postchallenge glucose 140 mg/dl;
isolated IFG—FPG 100–125 mg/dl and
2-h postchallenge glucose 140 mg/dl;
isolated IGT—FPG 100 mg/dl and 2-h
postchallenge glucose 140–199 mg/dl;
any IFG—FPG 100–125 mg/dl and 2-h
postchallenge glucose 199 mg/dl; any
IGT—FPG 126 mg/dl and 2-h post-
challenge glucose 140–199 mg/dl; com-
bined IFG and IGT—FPG 100–125
mg/dl and 2-h postchallenge glucose
140–199 mg/dl; and diabetes—FPG
126mg/dlor2-hpostchallengeglucose
200 mg/dl. Isolated IFG was further
subcategorized into fasting glucose be-
tween100and109mg/dl(IFG100–109)
and fasting glucose between 110 and 125
mg/dl (IFG 110–125). All OGTTs were
begunbefore11:00 A.M.afteranovernight
fast, with blood samples drawn at base-
line,1h,and2h.Bloodsampleswerealso
obtained for measurement of plasma lip-
ids and A1C. Plasma glucose samples
were obtained using sodium ﬂuoride/
oxalate preservative. Plasma samples
were centrifuged, separated, and frozen
within 30 min. All samples were stored at
80°C until assayed. Chemical analyses
wereperformedinthecentralclinicallab-
oratory of the Grady Health System using
an LX-20 analyzer (Beckman Coulter,
Brea, CA); A1C measurement with this
system is National Glycohemoglobin
Standardization Program-certiﬁed.
Statistical analysis
In the NHANES III database, a subset of
adults aged 40 years had an OGTT per-
formed. We analyzed only those who had
no known history of diabetes, had com-
pleted the OGTT in the morning before
11:00 A.M.afteranovernightfastofatleast
9 h, for whom the 2-h postchallenge glu-
coselevelwasmeasuredbetween100and
135 min after ingestion of the glucose
load, and had a survey weight value 0.
Among this subset (n  2,833), we in-
cluded only those who were non-
Hispanic black or white (to match our
study population) (n  2,057).
In the NHANES 2005–2006 popula-
tion, all subjects 12 years who were
seeninthemorningsessionwereaskedto
have an OGTT performed. Subjects were
eligible for the OGTT if they had fasted
overnight for at least 9 h, reported no use
oforalmedicationsorinsulinfordiabetes,
were not pregnant, did not have hemo-
philia, and did not receive cancer chemo-
therapyintheprevious3weeks.Allblood
samples for the 2-h glucose measurement
were drawn between 100 and 135 min
afteringestionoftheglucoseload.Forour
analysis, we included only those who
were 18 years, had no known history of
diabetes, were non-Hispanic black or
white (to match our study population),
and had a survey weight value 0( n 
1,154). Because some subjects had more
than one blood pressure measurement,
theaverageofthemeasurementswasused
for the analysis.
For the SIGT, NHANES III, and
NHANES 2005–2006 subjects, age, BMI,
and A1C were categorized using the cut-
offs recommended by the ADA: age 60
years, BMI 35 kg/m
2, and A1C 6.0%
(8). Other risk factors for diabetes that
were not speciﬁcally deﬁned by the ADA
were categorized according to the Ameri-
can Heart Association/National Heart,
Lung, and Blood Institute (AHA/NHLBI)
diagnostic criteria for metabolic syn-
drome (12): presence of hypertension by
history, systolic blood pressure 130
mmHg or diastolic blood pressure 85
mmHg, triglyceride level 150 mg/dl,
and HDL cholesterol 40 mg/dl in men
and50mg/dlinwomen.Giventhehigh
number of subjects in NHANES III and
NHANES 2005–2006 whose reporting of
the diabetes status of one or more ﬁrst-
degree relatives was either not known or
left blank (NHANES III, n  1,163;
NHANES2005–2006,n116),relatives
whose diabetes status was missing or not
known were assumed to not have diabe-
tes, a method that was also implemented
for the analysis of the SIGT study group.
In addition, subjects with missing values
for the remaining risk factors were ex-
cluded from analysis (NHANES III: 1
missing blood pressure measurement or
hypertension history, 7 missing A1C val-
ues, 27 missing triglyceride values, and
35 missing HDL cholesterol values;
NHANES 2005–2006: 32 missing blood
pressure measurements or hypertension
history, 8 missing BMI measurements, 2
missing A1C values, 4 missing triglycer-
ide values, and 4 missing HDL values),
leaving2,014subjectsinNHANESIIIand
1,111 subjects in NHANES 2005–2006
to be analyzed for metformin consider-
ation.
Means and frequencies were deter-
minedinaggregateandbysubgroupanal-
ysis of the different glucose tolerance
categories. All SIGT analyses were per-
formed using SPSS 15.0 (SPSS, Chicago,
IL).AllNHANESIIIandNHANES2005–
2006 analyses were conducted using
SUDAAN statistical software (version 10)
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and all estimates were weighted (RTI In-
ternational, Research Triangle Park, NC).
RESULTS— Among 1,581 volunteers
who completed OGTTs in the SIGT
study, average age was 48 years and BMI
was30.3kg/m
2,42%weremale,and58%
were black (Table 1). In the selected
NHANES III population (n  2,014), the
average age was 55 years and BMI was
27.3 kg/m
2, 47% were male, and 10%
were black, and in NHANES 2005–2006
(n  1,111), the average age was 46 years
andBMIwas28.5kg/m
2,49%weremale,
and 13% were black (Table 1).
In the SIGT population, 62.1% had
normal fasting glucose and NGT, 18.0%
had isolated IFG, 7.2% had isolated IGT,
8.2% had both IFG and IGT, and 4.6%
haddiabetes,similartotheproportionsin
NHANES III (54.3% had NGT, 22.3%
had isolated IFG, 6.4% had isolated IGT,
9.4% had both IFG and IGT, and 7.6%
had diabetes) and NHANES 2005–2006
(59.1% had NGT, 21.8% had isolated
IFG, 5.0% had isolated IGT, 9.0% had
both IFG and IGT, and 5.2% had diabe-
tes). All three populations had a compa-
rable portion with either IFG or IGT
(33.4% in SIGT, 38.1% NHANES III, and
35.8% in NHANES 2005–2006).
When the associated risk factors for
diabetes, as speciﬁed by the ADA consen-
sus statement (8), were considered,
among those with both IFG and IGT, the
presence of each risk factor was generally
higher among SIGT subjects, compared
with subjects in NHANES III and
NHANES2005–2006,withtheexception
of elevated triglycerides and A1C levels
(Table2).Evenwiththedifferencesinthe
prevalence of risk factors, almost all sub-
jects with both IFG and IGT in all three
populations had at least one risk factor
(99% in SIGT, 96% in NHANES III, and
96% in NHANES 2005–2006), which
was similar among those with IFG (iso-
lated or with IGT: 99% in SIGT, 96% in
NHANES III, and 83% in NHANES
2005–2006) and those with IGT (isolated
or with IFG: 99% in SIGT, 96% in
NHANES III, and 94% in NHANES
2005–2006). Among all subjects with
IFG(isolatedorwithIGT),one-quarterto
one-third (31% in SIGT, 29% in
NHANES III, and 28% in NHANES
2005–2006)mettherecommendedcrite-
ria for metformin treatment, and among
all subjects with IGT (isolated or with
IFG), one-half to two-thirds (53% in
SIGT, 57% in NHANES III, and 62% in
NHANES 2005–2006) did so (Fig. 1).
Overall, 1 in 12 individuals in these
populations met the criteria for consider-
ation of metformin (8.1% in SIGT, 9.1%
in NHANES III, and 8.7% in NHANES
2005–2006).
CONCLUSIONS — In consideration
of the enormous public health impact of
diabetes and the evidence of beneﬁt
from pharmacological treatment for the
prevention of diabetes, the ADA issued
a consensus statement recommending
preventive treatment in individuals at
high risk of developing diabetes, deﬁned
as those with more severe pre-diabetes
Table 1—Characteristics of study subjects
SIGT NHANES III NHANES 2005–2006
n 1,581 2,014 (weighted) 1,111 (weighted)
Age (years) 48  0.3 55  0.5 46  1.0
Male sex (%) 42  0.01 47  1.1 49  1.7
Black (%) 58  0.01 10  0.8 13  2.1
BMI (kg/m
2) 30  0.2 27  0.2 28  0.2
A1C (%) 5.4  0.01 5.4  0.02 5.3  0.02
Glucose tolerance categories (%)
NGT 62.1  0.01 54.3  1.5 59.1  3.2
IFG isolated 18.0  0.01 22.3  1.4 21.8  1.9
IGT isolated 7.2  0.007 6.4  0.7 5.0  0.9
IFG and IGT 8.2  0.007 9.4  0.9 9.0  1.3
Diabetes 4.6  0.005 7.6  0.6 5.2  0.7
Data are means  SEM.
Table 2—Prevalence of risk factors for diabetes in study subjects
SIGT NHANES III NHANES 2005–2006
All
subjects
IFG
(IGT)
IGT
(IFG)
IFG 
IGT
All
subjects
IFG
(IGT)
IGT
(IFG)
IFG 
IGT
All
subjects
IFG
(IGT)
IGT
(IFG)
IFG 
IGT
n 1,581 2,014 (weighted) 1,111 (weighted)
Age 60 years 84 79 76 77 66 62 51 48 80 72 60 51
BMI 35 kg/m
2 22 27 30 38 9 11 11 12 16 23 27 30
Family history of diabetes 46 49 54 55 28 29 31 34 36 39 50 51
Triglycerides 150 mg/dl 13 18 18 21 37 45 53 50 28 37 47 55
Reduced HDL cholesterol* 47 54 57 64 40 44 47 50 21 23 29 29
Hypertension† 49 63 68 69 41 44 57 54 28 37 42 49
A1C 6.0% 7 10 12 18 8 9 11 13 6 9 11 17
1 risk factor 99 99 99 99 95 96 96 96 74 83 94 96
Metformin indicated‡ 8.1 31.0 52.7 99.2 9.1 28.6 57.3 96.2 8.7 28.2 61.7 96.2
Data are %. Glucose tolerance categories: IFG (IGT), IFG with or without IGT; IGT (IFG), IGT with or without IFG; IFG  IGT, both IFG and IGT. *Reduced
HDL cholesterol deﬁned as 40 mg/dl in men and 50 mg/dl in women. †Hypertension deﬁned by any of the following: history of hypertension, systolic blood
pressure 130 mmHg, or diastolic blood pressure 85 mmHg. ‡Metformin indicated per the ADA consensus statement (8) criteria of the presence of both IFG and
IGT and one of the following diabetes risk factors: age 60 years, BMI 35 kg/m
2, family history of diabetes, elevated triglycerides, reduced HDL cholesterol, and
A1C 6.0%. Risk factors for diabetes that were not speciﬁcally deﬁned by the ADA were categorized according to the AHA/NHLBI diagnostic criteria for metabolic
syndrome (12): presence of hypertension by history, systolic blood pressure 130 mmHg or diastolic blood pressure 85 mmHg, triglyceride level 150 mg/dl,
and HDL cholesterol 40 mg/dl in men and 50 mg/dl in women.
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risk factor) (8). To determine the propor-
tionofindividualswhowouldbetargeted
by such a recommendation, we examined
a relatively healthy population without
previouslydiagnoseddiabetes(SIGT)and
representative samples of the U.S. popu-
lation (NHANES III and NHANES 2005–
2006) and found that one-quarter to one-
thirdhadpre-diabetes.Amongthosewith
IFG, nearly one-third of subjects met the
criteria for consideration of metformin
treatment to prevent diabetes in accor-
dance with the recent ADA consensus
statement,morethanone-halfofallofthe
subjectswithIGTqualiﬁed,andalmostall
of those with both IFG and IGT qualiﬁed.
Overall,8–9%mettherecommendedcri-
teria. Assuming that our data are general-
izable to the U.S. population, 24
million Americans might beneﬁt from
pharmacological treatment in addition to
lifestyle modiﬁcation.
The epidemic of diabetes and the in-
sidious onset of its complications have
prompted a call for early identiﬁcation
and preventive treatment of the disease.
Diabetes is currently the leading cause of
blindness, end-stage renal disease requir-
ing dialysis, and nontraumatic amputa-
tions in the U.S. and increases the risk for
cardiovascular disease and stroke by two-
to fourfold, compared with those without
diabetes (1). It is the seventh leading
cause of death (1) and in 2007 cost $174
billion in both direct and indirect health
care expenditures (2). In addition, the
prevalenceofdiabeteshasbeenontherise
in the adolescent population (13), indi-
cating that the epidemic is likely to con-
tinue into the next generation.
Pre-diabetes, the stage preceding the
development of diabetes, increases the
riskforthedevelopmentofdiabetes,such
that 25–39% of patients with IFG or IGT
go on to develop diabetes over a period of
5–10 years (14,15). Moreover, pre-
diabetes alone has been associated with
an increased risk for the development of
cardiovasculardisease(16,17)andmicro-
vascular complications typically seen
withdiabetes(18).Giventheserisks,pro-
spective studies have been conducted to
identify preventive treatment. In addition
to lifestyle modiﬁcation, pharmacological
treatmentwithacarbose(5),rosiglitazone
(6), orlistat (19), or metformin (4) has
shown efﬁcacy in preventing or delaying
the onset of diabetes in individuals with
pre-diabetes. The relative risk reduction
for diabetes in the pre-diabetic popula-
tion was 25% over 3.3 years in patients
treated with acarbose (5), 52–62% over
2–4 years with orlistat (19), 62% over 3
years with rosiglitazone (6), and 26–31%
over 2.5–2.8 years with metformin (4).
However, because many individuals with
pre-diabetes are generally healthy, the
beneﬁt of preventive treatment must out-
weigh any associated side effects or addi-
tional risks, particularly because none of
these medications have U.S. Food and
Drug Administration approval for the in-
dicationofdiabetesprevention.Gastroin-
testinal side effects are commonly
associated with acarbose (5) and orlistat
(19), leading to poor patient compliance,
whereas an increased risk of bone loss
Figure 1—Prevalence of metformin indication, stratiﬁed by glucose tolerance category. Metformin is indicated per the ADA consensus statement
criteriaofthepresenceofbothIFGandIGTandoneofthefollowingdiabetesriskfactors:age60years,BMI35kg/m
2,familyhistoryofdiabetes,
elevated triglycerides, reduced HDL cholesterol, and A1C 6.0% (8). Risk factors for diabetes that were not speciﬁcally deﬁned by the ADA were
categorized according to the AHA/NHLBI diagnostic criteria for metabolic syndrome (12): presence of hypertension by history, systolic blood
pressure130mmHgordiastolicbloodpressure85mmHg,triglyceridelevel150mg/dl,andHDLcholesterol40mg/dlinmenand50mg/dl
inwomen.Glucosetolerancecategoriesareasfollows:IFG100–109,FPGlevels100–109mg/dland2-hpostchallengeplasmaglucose140mg/dl;
IFG 110–125, FPG 110–125 mg/dl and 2-h postchallenge plasma glucose 140 mg/dl; all IFG, isolated IFG (FPG 100–125 mg/dl and 2-h
postchallenge plasma glucose 140 mg/dl); IGT, isolated IGT; and IFG 100–125  IGT, all IFG and IGT.
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(21), and heart failure (22) are associated
with rosiglitazone. Therefore, metformin,
whichhasbeenusedformanyyearsandis
both generally well tolerated and rela-
tively safe, has become the leading candi-
date for preventive treatment.
In addition to the recommendations
of the ADA, the American College of En-
docrinology (ACE) has recently issued
theirconsensusstatementonthemanage-
ment of pre-diabetes (23). Similar to the
ADA recommendations, the ACE state-
ment recognizes the need for preventive
treatment, beginning with lifestyle modi-
ﬁcation, but also emphasizes the impor-
tance of treating relevant comorbid
conditions, such as hypertension, hyper-
cholesterolemia, and obesity, and pro-
vides a looser set of criteria regarding the
initiation of pharmacological treatment.
Acarbose and metformin are their recom-
mended treatments for individuals who
are at high risk of developing diabetes,
which include, but are not limited to,
thosewithIFG,IGT,and/orthemetabolic
syndrome, worsening glycemia, cardio-
vascular disease, nonalcoholic fatty liver
disease, a history of gestational diabetes,
or polycystic ovary syndrome. Taking
into account the target populations as de-
ﬁned by the ADA and the ACE, 8% of
Americans could beneﬁt from pharmaco-
logical treatment to prevent or delay de-
velopment of diabetes.
Use of pharmacological agents for the
many Americans who may beneﬁt from
preventive treatment would incur sub-
stantial costs: at current generic rates for
metformin, possibly $4/month  12
months  24 million Americans  $1.15
billion per year. However, several studies
suggest that diabetes prevention or delay
with metformin is likely to be cost-
effective and/or cost-saving (24); further
evaluation using a variety of cost analysis
methods may be required to reach a de-
ﬁnitive conclusion regarding the cost of
preventive treatment.
To our knowledge, our ﬁndings are
the ﬁrst evaluation of the proportion of
relatively healthy individuals who might
beneﬁt from metformin treatment for the
prevention or delay of development of di-
abetes. However, our study has limita-
tions. Because all SIGT subjects were
recruited on a volunteer basis, there may
have been a selection bias toward higher
family history of diabetes and/or other
risk factors for diabetes. Therefore, the
SIGT population may represent a group
ofindividualsathigherrisk.However,be-
cause many SIGT subjects were recruited
from university and health care settings,
they may also follow healthier lifestyles,
which could offset such a bias. Moreover,
the proportion with diabetes or pre-
diabetes in SIGT was no higher than that
in NHANES III and was comparable to
that in the more recent NHANES 2005–
2006, both of which represent random-
ized, stratiﬁed samples of the American
population.
The morbidity, mortality, and cost of
theepidemicofdiabeteshaveprompteda
call for primary prevention of diabetes in
high-risk individuals by the use of met-
formininadditiontolifestylechanges.To
the extent that our ﬁndings are represen-
tative of the U.S. population, close to 1 in
12 American adults may meet the recom-
mended guidelines for consideration of
metformin treatment for diabetes preven-
tion or delay. Notably, eligibility for met-
formin use appeared to be almost
completely determined by impaired glu-
cose metabolism alone, because 99% of
the SIGT population and 96% of the
NHANES populations with both IFG and
IGThadatleastoneriskfactor.Therefore,
once the presence of both IFG and IGT
has been established, the presence of ad-
ditional risk factors could almost be as-
sumed, and initiation of metformin
should be considered. Moreover, because
nearly one-third of all subjects with IFG
met the criteria for metformin treatment,
providers should perform OGTTs in all
patients with IFG to test for the presence
of IGT (or unrecognized diabetes) and
thereby determine whether they merit
consideration of metformin treatment.
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